Previous Close | 0.3000 |
Open | 0.0000 |
Bid | 0.2850 x 0 |
Ask | 0.3000 x 0 |
Day's Range | 0.0000 - 0.0000 |
52 Week Range | |
Volume | |
Avg. Volume | 13,668 |
Market Cap | 11.078M |
Beta (5Y Monthly) | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1230 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Mar 08, 2016 |
1y Target Est | N/A |
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnership
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that that it has changed its auditor from MNP LLP (the "Former Auditor") to Clearhouse LLP (the "Successor Auditor"). The Former Auditor resigned effective May 27, 2022, at the Company's request, and the Company's board of directors appointed the Successor Auditor to fill the resulting vaca
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab's products and to assist Canntab in reaching strategic partnerships in the Cannab